Literature DB >> 30651669

Physaliphorous cells.

Deepak Pandiar1, Smitha Thammaiah2.   

Abstract

Entities:  

Year:  2018        PMID: 30651669      PMCID: PMC6306593          DOI: 10.4103/jomfp.JOMFP_265_18

Source DB:  PubMed          Journal:  J Oral Maxillofac Pathol        ISSN: 0973-029X


× No keyword cloud information.
In histopathology, characteristics of nucleus and cytoplasm often give diagnostic clues. While some features are suggestive of a particular lesion, others are indispensable and are pathognomonic. Here, we would like to discuss “physaliphorous or physaliferous cells,” characteristic cells (if not pathognomonic) seen in chordoma which is a rare malignant tumor derived from the embryonic notochordal remnants.[1] In the head-and-neck region, clivus is the most commonly involved site with a male predominance. Physaliphorous is a combination of two words – Greek word Physallis meaning “bubble” and Phoros meaning “bearing.” Thus, physaliphorous cells literally mean cells having bubbly or vacuolated appearance. Figure 1 shows hematoxylin and eosin photomicrograph of sheets of the large polygonal cells with distinct cell outline, clear or vacuolated eosinophilic cytoplasm and small round central or eccentric open-face nuclei. Hand-drawn image of a physaliphorous cell is demonstrated in Figure 2. Typically, these cells are seen in the cords or lobules separated by the thin fibrocellular septa [Figure 3]. Variable amount of nuclear pleomorphism may be seen. Chondroid chordoma is a term given where hyaline cartilage-like matrix is found in between the lobules of “physaliphorous cells.” Other variants include dedifferentiated chordoma consisting of areas of undifferentiated sarcoma with classic type.
Figure 1

Sheets of large cells with bubbly cytoplasm and small round nucleus (H and E, ×100)

Figure 2

Hand-drawn illustration of physaliphorous cell showing abundant vacuolated cytoplasm (1) and small round centrally nucleus (2)

Figure 3

Lobules of physaliphorous cells separated by the fibrous septa (hematoxylin and eosin, ×40)

Sheets of large cells with bubbly cytoplasm and small round nucleus (H and E, ×100) Hand-drawn illustration of physaliphorous cell showing abundant vacuolated cytoplasm (1) and small round centrally nucleus (2) Lobules of physaliphorous cells separated by the fibrous septa (hematoxylin and eosin, ×40) The exact nature of these cells is not clearly understood. The vacuolated structure of the physaliphorous cells corresponds to the structure of the notochord consisting of large chordocytes with prominent vacuoles. Ultrastructurally, two types of vacuoles have been described, namely, villous vacuoles and smooth-walled vacuoles.[2] Another early electron microscopic study showed that small vacuoles represent dilated cisterns of the coarse endoplasmic reticulum, while the large ones are derived from sequestrations of the interstitial material.[3] The size of the physaliphorous cells can reach up to 50 μs or more. These cells show immunohistochemical expression of pan-cytokeratin [Figure 4], EMA, S100 and brachyury. It was previously believed that the large vacuoles store sulfated glycosaminoglycans; Lam R, in contrast, showed that these vacuoles form as a result of breakdown and utilization of membrane-bound glycogen in the biosynthesis of sulfated glycosaminoglycans.[4]
Figure 4

Photomicrograph showing diffuse pan-cytokeratin positivity (immunohistochemistry)

Photomicrograph showing diffuse pan-cytokeratin positivity (immunohistochemistry) Apart from the skull base, sacrum and spine are other most commonly affected sites. T (brachyury) gene duplication is shown in rare cases of familial chordoma.[5] Complete surgical resection of the tumor is the most important prognostic factor.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  1 in total

1.  A rare case of chordoma presenting as a Pancoast tumor.

Authors:  Philip T Sobash; Krishna Vedala; Daniel Alfano; Heather Pinckard-Dover; Jason L Muesse; Raman Desikan
Journal:  Rare Tumors       Date:  2021-07-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.